August 16, 2025BMC CancerOpen Access

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

View Full Paper

Ask AI

Bookmark

Authors

YXYang XiaoUniversity of Shanghai for Science and Technology YDYuhong DaiTongji Hospital HPHui Peng

Discussion

Member takes

Implication

Randomised phase II trial compares nab-paclitaxel plus cisplatin to gemcitabine plus cisplatin in advanced biliary cancer, suggesting non-inferior outcomes.

Key Points

Progression-free survival was significantly higher in the nab-paclitaxel group compared to the gemcitabine group, indicating potential advantages.
Median progression-free survival was 7.8 months for the nab-paclitaxel group and 7.0 months for the gemcitabine group, with a notable p-value of 0.0034.
Multicentre phase II trial involved patients with advanced biliary tract cancer, assessing outcomes like overall survival and safety.
Findings highlight the need for further research to establish the efficacy and safety of nab-paclitaxel in modern treatment settings.

Cite This Study

Xiao et al. (2025) studied this question.

synapsesocial.com/papers/68af2d7ccf1dd9ea359e5956 https://doi.org/10.1186/s12885-025-14581-3

View Full Paper

Ask AI

Bookmark

Implication

Randomised phase II trial compares nab-paclitaxel plus cisplatin to gemcitabine plus cisplatin in advanced biliary cancer, suggesting non-inferior outcomes.

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider